Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AstraZeneca PLC and Bristol-Myers Squibb XIGDUO receives approval in european union for type 2 diabetes


Wednesday, 22 Jan 2014 02:00am EST 

AstraZeneca PLC and Bristol-Myers Squibb:Says Xigduo (dapagliflozin and metformin hydrochloride in 5mg/850mg and 5mg/1000mg tablets) has been granted Marketing Authorisation by the European Commission for the treatment of type 2 diabetes in the European Union (EU).Says Xigduo combines dapagliflozin (trade name Forxiga), a selective and reversible inhibitor of SGLT2 with metformin hydrochloride, two anti-hyperglycaemic products with complementary mechanisms of action to improve glycaemic control, in a twice daily tablet.Says this is the first regulatory approval for a fixed dose combination of an SGLT2 inhibitor and metformin. 

Company Quote

4421.0
-5.0 -0.11%
11:36am EDT